For research use only. Not for therapeutic Use.
Favezelimab（Cat No.:I042107）is an investigational monoclonal antibody that targets the immune checkpoint receptor PD-1 (programmed cell death protein 1). By blocking PD-1, favezelimab aims to enhance the immune system’s ability to recognize and attack cancer cells, counteracting the mechanism by which tumors evade immune detection. It is being evaluated in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and melanoma. As a checkpoint inhibitor, favezelimab is being studied alone and in combination with other treatments to assess its effectiveness and safety in improving cancer patient outcomes.
| Catalog Number | I042107 |
| CAS Number | 2231068-83-8 |
| Purity | ≥95% |
